| abstract |
The invention relates to ciclosporin-loaded solid particulate drug carriers based on lipids with improved biopharmaceutical properties for ciclosporins in vivo, improved quality (fineness and uniformity of the particles, drug inclusion) and improved physical stability of the particulate formulation (absence of aggregation and gel formation). The invention further comprises a therapeutic treatment with cyclosporin formulations which have an average blood level concentration in the steady state range from 300 ng / ml to more than 1000 ng / ml, preferably more than 800 ng / ml, in particular up to 900 ng / ml, preferably 400 ng / ml ml to 800 ng / ml in the absence of high initial blood concentrations above 1200 ng / ml, which preferably lasts for a prolonged period of at least 5 h, preferably at least 7 h. |